Clinical trials
Hypersensitivity trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
85 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 10 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 7 |
| 2022 | 7 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 59 |
| Unknown status | 7 |
| Terminated | 6 |
| Recruiting | 4 |
| Active, not recruiting | 4 |
| Withdrawn | 3 |
| Enrolling by invitation | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Allergy Therapeutics | 12 |
| Circassia Limited | 7 |
| University of British Columbia | 4 |
| Aimmune Therapeutics, Inc. | 3 |
| AstraZeneca | 3 |
| McMaster University | 3 |
| Novartis Pharmaceuticals | 3 |
| Pfizer | 3 |
| ALK-Abelló A/S | 2 |
| Celgene | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypersensitivity | 85 |
| Hypersensitivity, Immediate | 23 |
| Asthma | 15 |
| Immune System Diseases | 11 |
| Rhinitis, Allergic, Seasonal | 9 |
| Rhinitis | 6 |
| Rhinitis, Allergic | 6 |
| Anaphylaxis | 5 |
| Peanut Hypersensitivity | 5 |
| Skin Diseases | 5 |
Trials
Showing 26 to 50 of 85. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.